Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Assess Safety and Efficacy of SIR1-365 in Patients With Severe COVID-19

NCT04622332 is registered in ClinicalTrials.gov with Sironax USA, Inc. as lead sponsor.

NCT NCT04622332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04622332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Assess Safety and Efficacy of SIR1-365 in Patients With Severe COVID-19
Lead sponsor
Sironax USA, Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 18, 2020
Completion date
November 27, 2021
Enrollment
45 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

corona virus infection